These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11319593)

  • 1. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
    Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
    Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation.
    Batsis I; Yannaki E; Kaloyannidis P; Sakellari I; Smias C; Georgoulis I; Fassas A; Anagnostopoulos A
    Thromb Res; 2006; 118(5):611-8. PubMed ID: 16330084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation.
    Gluckman E; Jolivet I; Scrobohaci ML; Devergie A; Traineau R; Bourdeau-Espérou H; Lehn P; Faure P; Drouet L
    Nouv Rev Fr Hematol (1978); 1990; 32(1):1-3. PubMed ID: 2349075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
    Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation.
    Cheuk DK; Chiang AK; Ha SY; Chan GC
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD009311. PubMed ID: 26017019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
    Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Callander NS; Clement DJ
    Bone Marrow Transplant; 1992 Oct; 10(4):367-72. PubMed ID: 1422493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution.
    Kami M; Mori S; Tanikawa S; Akiyama H; Onozawa Y; Tanaka T; Okamoto R; Maeda Y; Sasaki T; Kaku H; Matsuura Y; Hiruma K; Sakamaki H
    Bone Marrow Transplant; 1997 Sep; 20(5):397-402. PubMed ID: 9339756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
    Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA
    Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
    Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM
    Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of hepatic veno-occlusive disease by a combination of heparin and prostaglandin E1 in children undergoing hematopoietic stem cell transplantation].
    Inukai T; Sugita K; Goi K; Akahane K; Hirose K; Nemoto A; Takahashi K; Sato H; Uno K; Furuichi Y; Nakamura M; Miyamoto N; Yamakawa N; Shiraishi K; Kojika S; Tezuka T; Iijima K; Nakazawa S
    Rinsho Ketsueki; 2004 Apr; 45(4):297-303. PubMed ID: 15168445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin.
    Rio B; Bauduer F; Arrago JP; Zittoun R
    Bone Marrow Transplant; 1993 Jun; 11(6):471-2. PubMed ID: 8334428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prophylaxis of hepatic veno-occlusive disease by low-molecular-weight heparin and lipo- prostaglandin E1 after allogeneic peripheral blood stem cell transplantation].
    Song CY; Li YH; Guo KY; Wu BY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 May; 23(5):494, 497. PubMed ID: 12754143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
    Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
    J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
    Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients.
    Hahn T; Rondeau C; Shaukat A; Jupudy V; Miller A; Alam AR; Baer MR; Bambach B; Bernstein Z; Chanan-Khan AA; Czuczman MS; Slack J; Wetzler M; Mookerjee BK; Silva J; McCarthy PL
    Bone Marrow Transplant; 2003 Aug; 32(4):405-10. PubMed ID: 12900777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
    Dong M; Lin Q; Wu XY
    Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.